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The summarized results of 25-year studies of department of human genomics of IMBG NASU are presented. The
investigations were focused on identification of molecular genetic nature of human genome coding and non-co-
ding region mutations (genetic polymorphisms) and rearrangements, their spectrum, and origin in Ukrainian
population. The role of genome heterogeneity in some severe monogenic and complex disorder pathogenesis has
been shown. The data concerning correlation between certain determinator gene mutations and phenotypical
manifestation of most common in Ukraine monogenic diseases have been demonstrated. Moreover, the role of
modifying genes in specific clinical phenotype variations has been shown. Origin of particular mutant alleles and
main mechanisms of their frequency maintenance in Ukrainian population have been investigated. The data
about association of some polymorphic variants with infertility, cardiovascular diseases (ischemic stroke) as well
as mass infectious diseases (hepatitis C, AIDS) outcome and standard therapy efficiency have been presented. The
first results and prospects for candidate genes of neurodegenerative disorders and intellectual disability search
using whole genome CNVs screening are shown.
Keywords: human genomics, genotype, phenotype, genetic polymorphism, genetic marker.
Inroduction. Despite the official end of «Human Geno-
me» program, the studies initiated in this project are endu-
ring. Structural and functional genome organization and
DNA sequence polymorphism are still of great interest
for research. According to the project results, open rea-
ding frame DNA regions cover only 1.5 % of genome.
It is estimated that human genome comprises 20–25
thousand genes. Information about 14200 mapped human
genes is provided by Online Mendelian Inheritance in
Man® – OMIM® database. Nearly 98 % of human genome
nucleotide sequences which are not expressed (regulato-
ry elements, satellite DNA) fall into non-coding DNA.
ENCODE (Encyclopedia of DNA Elements – star-
ted in 2003) is one of the projects focused on the separa-
te gene function elucidation. In the framework of this
project researchers attempt to classify and identify func-
tional elements in human genome.
The data concerning variability of certain genome re-
gions have become an important result with theoretical
and practical implications. Despite the high level of geno-
me DNA conservation and robust mechanisms of its sta-
bility maintenance, some mutations appeared to have
been spreading in the population leading to genetic poly-
morphism (allelic variation).
Theoretically, genome variability creates the basis of
population genetics for the analysis of selection and mig-
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ration – the most important factors influencing mutage-
nesis and mutation expansion.
According to OMIM® database, which is being con-
stantly updated, molecular genetic nature has been de-
termined (determinator genes have been identified) for
3,739 hereditary diseases. The most large-scale projects
devoted to human genome polymorphisms study are
«ÍàðÌàð» (2002–2006) and «1000 genomes» (2007).
The data obtained in the frame of these projects have be-
come a basis for new monogenic hereditary disorders
and hereditary sensitivity for complex disorders candi-
date gene search. All these studies have become the sub-
ject of modern science – genomics. Basically, human
genomics apart from fundamental knowledge have prac-
tical implications for biomedicine in terms of working out
a new strategy for diagnostics, prevention, and treatment.
Studies focused on identification of molecular ge-
netic nature of human genome coding and non-coding
region mutations (genetic polymorphisms) and rearran-
gements, their spectrum, and origin in Ukrainian popu-
lation have been conducted in department of human ge-
nomics of IMBG of NAS of Ukraine for 25 years.
Origin and gene geography of mutations associated
with monogenic disorders. It has been shown that muta-
tions can occur as a consequence of one genetic event
with the following expansion in population (single
origin), the same mutation can also occur repeatedly in
different populations (recurrent origin). So, specific spec-
trum and frequency of mutations are characteristic of
every gene including ones associated with pathologies.
We have conducted studies on the mutation origin and
gene geography for genes CFTR, PAH, ²Ò15, TGFBI
causing the most common monogenic disorders: cystic
fibrosis (CF), phenylketonuria (PKU), Huntington’s di-
sease (HD), stromal corneal dystrophy (SCD) respecti-
vely, in order to obtain profound and integrated know-
ledge about regularities of mutagenesis and mutation
maintenance in Ukrainian population.
Deletion of 3 nucleotides in 10th exon – delF508,
has been determined by many studies as the major mu-
tation of CFTR gene. This mutation frequency in CF
patients from Ukraine amounted to 47.8 % (Fig. 1). The
statistically significant linkage disequilibrium delF508
mutation and certain alleles of polymorphic markers
was shown in Ukrainian population as well as in many
world populations. It supports the hypothesis about
single origin of delF08 mutation [1, 2] in European po-
pulations.
Two distinct approaches were used in order to si-
mulate an approximate time interval of this mutation
occurrence within the territory of Ukraine, which
amounted from 2440 to 4060 years [2]. The first one is
based on CFTR gene cross over minihaplotype frequen-
cies and the second one is based on the data about
delF08 frequency in modern Ukrainian population and
the hypothesis about this mutation selective advantage.
In the frame of collaborative study the so-called «Sla-
vic» mutation CFTRdele2,3 (2,1 kb) in 5'-region of
CFTR gene has been identified. It measures 21 kb, in-
volves introns 1–3, exons 2 and 3, and is spread only in
Slavic origin populations, with 1.2 % frequency in Uk-
rainian population [3].
Molecular genetic analysis of ÐÀÍ (phenylalanine
hydroxylase) gene has established that R408W is a ma-
jor mutation among PKU patients in Ukraine, and its
frequency is 57 % [4]. The results of segregation ana-
lysis between this mutation and ÐÀÍ gene intragenic
polymorphic minihaplotypes have shown two European
centres of R408W origin (Fig. 2). According to the re-
sults of the association between R408W mutation and
minihaplotype VNTR03/STR238 analysis in PKU pa-
tients from Ukraine, the single Balto-Slavic origin of
this mutation in our population has been identified [5].
The studies on frequency, paternal origin of inheri-
tance, dynamic mutation in CAG-repeat of ²Ò15 gene,
which is the main cause of HD, have been conducted.
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Fig. 1. CFTR gene mutation delF508 frequency in patients and healthy
individuals from different regions of Ukraine – delF508 carrier frequen-
cies in regional populations of Ukraine
²Ò15 gene minihaplotype segregation analysis has pro-
ven the recurrent origin of CAG-repeat expanded alle-
lic variants (alleles with more than 40 repeats) in HD
group from Ukraine [6].
The molecular study on hereditary stromal corneal
dystrophies as an important problem of ophtalmogeno-
mics has become an essential focus area of our investi-
gation. The data concerning spectrum and frequency of
causing gene TGFBI mutation in Ukrainian population
were determined [7]. A novel mutation in exon 12 of
TGFBI gene (Leu558Pro) has been identified as well as
a new atypical clinical form of corneal dystrophy in pa-
tients with this mutation has been described (Fig. 3). On
the basis of revealed similar TGFBI gene minihaploty-
pes in patients with Leu558Pro mutation, the origin of
this mutation from one ancestrial founder was proven
[8, 9].
It is established that the presence of genetic poly-
morphism of different loci in human genome is the re-
sult of mutational process. In order to evaluate the fre-
quencies of de novo inherited mutations in some micro-
and minisatellite loci of nontranscribed genome re-
gions the allelic variants in nuclear families members
(father, mother, children) have been analysed. The le-
vel of inherited mutations for 9 studied autosomal mic-
rosatellite loci was evaluated as 3.1 10
–4 and 3.6  10
–3
for maternal and paternal origin correspondingly [10].
The average level for 9 Y-chromosome STRs was 1.5 
10–3 (The Y Chromosome Haplotype Reference Data-
base – YHRD). The frequency of inherited mutations
analysed in 7 minisatellite loci was evaluated in ranks
from 1.4  10
–1 to 67  10
–3. It is interesting to note the
unusually high mutability rate (14 %) revealed for mi-
nisatellite locus ÑÅÂ1. It has been established that the
majority of inherited mutations in the studied mini-
satellite loci are gains and de novo originated in male
germ cells [11].
Comparative analysis of CEB loci inherited muta-
tions in the children of Chernobyl accident liquidators
and from control group has shown that mutation level in
the studied group was 1.5 times higher. However such
differences were observed only in the group of children
conceived during 30 days after their parents’ exposure
[11]. It was supposed that the excess of inherited muta-
tions in children conceived during or immediately after
the end of their parents’ work at Chernobyl is a consequ-
ence of mutagenic effect of ionizing radiation on germ
cells during meiosis and sperm maturation and not on
stem germ cells [11].
High frequency (20.8 %) of 17ð11.2 region de novo
duplication (contains gene ÐÌÐ22 of peripheral mye-
lin), has been shown in families with hereditary demye-
linating polyneuropathy type 1 (CMT1À) [12].
It was also determined that high frequency (nearly
100 %) of dynamic mutation in CAG-repeat region of
²Ò15 gene inherited from father can be explained by
structural changes (mutations) in region flanking CAG-
repeats. On the other hand, it is determined that ²Ò15 ge-
ne mutant alleles are more stable in female gametoge-
nesis and in case of dynamic mutation originating du-
ring oogenesis a decrease of expanded repeats number
is observed more often. The obtained data explain geno-
mic imprinting and anticipation phenomena (more seve-
re manifestation in descendant when inheriting the mu-
tation from father) appearing in HD (Fig. 4) [6].
Genotype-phenotype association study in patients
with monogenic hereditary pathologies. Genotype-
phenotype correlation analysis is the characteristics of
association between specific mutant variants in patient’s
genome and clinical manifestations of pathology. This
analysis is essential both in terms of studying disease
development mechanism in general and its different cli-
nical characteristics in particular, moreover it is very
important to search for the best healthcare strategy for
patients and their families. We have studied variation
of main clinical characteristics in patients with different
mutant genotypes and association of various mutation
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Fig. 2. Two centers of PAH gene R408W mutation origin according
to the R408W-2.3 minihaplotype frequencies in Europe, – R408W-2.3
haplotype frequency in PKU-patients
with main parameters of clinical phenotype – age of ma-
nifestation, progression, severity of pathological chan-
ges at the levels of organs and systems. It is shown that
in some cases (in CF, PKU, fragile X-chromosome synd-
rome, and spinal muscular atrophy) it is possible to es-
tablish precise correlation between certain mutant va-
riants and specific clinical subtypes of the disease.
Majority of CF patients with delF508 in genotype
have the highest levels of chlorides in sweat and the
most severe form of disease (lung-gastric form with pan-
creal failure) [13].
Wide enough variation in phenotypical features of
fragile X syndrome (Martin-Bell syndrome) including
mental function peculiarities in both patients with ex-
panded CGG-region of FMR1 gene (full mutation) and
women-carriers of pre-mutation can be associated with
somatic mosaicism (the presence of alleles with diffe-
rent number of CGG-repeats) which we have observed
practically in all these individuals [14, 15]. It is suppo-
sed that the presence in different tissues and primarily
in brain neurons of alleles with various changes of gene
sequence can stipulate large stage-specific and tissue-
specific variation of the gene expression [13]. Negative
correlation between age of HD manifestation and CAG-
repeat number in expanded allele of ²Ò15 gene, and the
presence of 3-nucleotied deletion in 58th exon of the ge-
ne are established [6].
Genotype analysis in patients with different clinical
forms of PKU showed that «classic» severe form of the
disease is characteristic of homozygotes and compound
carriers of ÐÀÍ gene R408W mutation [4].
Clear association of clinical phenotype manifes-
tation in patients with SCD and different mutations of
TGFBI gene was revealed in study of large cohort of
patients from Ukraine. Vast majority of patients from 18
analysed families with Arg124Cys mutation had clini-
cal features of lattice corneal dystrophy type 1. Associa-
tion analysis between Arg555Trp mutation and clinical
characteristics of SCD showed that all carriers of this
mutation have symptoms of Groenouw SCD. Lattice cor-
neal dystrophy type IIIA phenotype is associated with
His626Arg mutation. Carriers of novel Leu558Pro mu-
tation had SCD clinical features significantly different
from previously described in literature (manifestation,
course, morphological peculiarities). It afforded us the
ground to distinguish it in separate nosological form of
corneal dystrophy [7].
Investigation in group of patients with hereditary
polyneuropathy allowed us to establish that heterozy-
gous deletion of 17ð11.2 region ÐÌÐ22 gene is asso-
ciated with recurrent neuropathy with pressure palsies,
whereas the duplication of this gene is identified in pa-
tients with CMT1A1 [12].
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Fig. 3. Novel mutation L558P in the TGFBI gene identified in patients
from Ukraine with atypical corneal dystrophy: A – sequence chroma-
togram from exon 12 of the TGFBI gene, demonstrating the region around
codon 558, illustrates a heterozygous T to C transition. This change pre-
dicts a leucine (CTC) to proline (CCC) replacement in residue 558
(L558P); the sense strand is shown; codon 558 underlined; B – retroillu-
mination showing numerous semi-transparent round and dot-like opaci-
ties in the central stroma, and fine lattice lines peripheral of central zo-
ne red pupil background; C – detection of the TGFBI gene L558P mu-
tation of the in patients with late corneal dystrophy by the PCR-RFLP
method in 10 % PAAG. PCR product digested by HinfI: 1, 2 – normal
homozygotes; 3–5 – mutant heterozygotes
On the other hand, it was shown that for the majori-
ty of monogenic pathologies the phenotypical variety is
observed, which cannot be explained with just determi-
nator gene mutant allele genotype of patient. It allows
us to suppose the existence of other factors, including
phenotype modifying genes. Modifying genes are consi-
dered to be mutant variants of genes, different from
main mutant gene, which determines pathogenesis. We
have proven the hypothesis that hemochromatosis gene
(HFE) modifies clinical phenotype of CF. It is establi-
shed that among the patients with the same CFTR gene
mutation genotype,HFE gene mutations carrying is as-
sociated with gastrointestinal system pathologies [16].
Study on the genotype-phenotype association in patients
with SMA revealed correlation between severity and
the size of deletion in 5q13 region. In the worst case the
deletion involves not only determinator gene SMN1 but
alsoNAIP gene, which is a phenotype modifier for this
pathology [13, 17].
The interesting data prove the association between
HD early manifestation and carrying substitution Ñ677Ò
in MTHFR gene, involved in homocysteine metabolism
[6]. We have also established that –174C allele of IL6
gene may be considered as a genetic marker of recur-
rent erosion development risk in patients with lattice
SCD, whereas –781ÒT genotype of IL8 gene is asso-
ciated with the absence of recurrent erosion in such pa-
tients [18].
For monogenic pathology, numerous evidences of
clear association between mutant genotype of determi-
nator gene and clinical phenotype have been obtained.
On the other hand, large variation of specific clinical
features is associated with modifying genes.
Study on genome polymorphism association with
risk of complex diseases. Studies, showing that varia-
tions of phenotypic manifestations in patients with iden-
tical mutations in the monogenic disease determining
genes can be caused by the presence of common in many
populations polymorphic variants of other genes, have
led to the wide genome association studies of allelic po-
lymorphisms in many genes and the risk of not only mo-
nogenic but also complex pathologies.
Over the last decade, investigations of complex di-
seases’ genetic factors have been developing rapidly.
Molecular genetic analysis of polymorphic variants in
genes, that individually play a minor role in the patho-
genesis of complex diseases, but in combination with
other endogenous and exogenous factors greatly increa-
se the risk, plays an important role in molecular aetio-
logy studies: cardiovascular disorders (including ische-
mic stroke), bronchial asthma, etc.
In our department the allelic variants analysis in ge-
nes involved in the pathogenesis of diminished ovarian
reserve (FMR1, INH, FSHR, ESR, GSTP1) is conduc-
ted. According to the calculation of statistically signifi-
cant factors of relevant risk OR (Odds Ratio), in our stu-
dy it has been proved that polymorphic variants ofFSHR
gene (Ala307-Ser680), INH (769G  A) ESR1 gene-
397T allelic variant, GSTP1 (313 A G) and FMR1
(«grey zone» alleles containing 40–47 CGG repeats)
can be used as markers for the genetic testing in order to
predict the high risk of premature ovarian failure and
poor response to intense exogenous gonadotropin sti-
mulation of superovulation in assisted reproductive
technology programs (Fig. 5) [19–21].
CAG repeats in the exon 1 of androgenic receptor
gene (AR) in many cases are the cause of oligospermia
and azoospermia. Moreover, our results show that short
alleles of AR gene (less than 18 CAG repeats) are asso-
ciated with azoospermia development, while the long
alleles (more than 28 CAG repeats) are associated with
oligospermia [22].
Our department activity is also focused on the ana-
lysis of genome polymorphic variants of affected indi-
viduals with cardio-vascular pathologies. It was estab-
lished that mutant variant 677Ò of MTHFR gene, D al-
lele (deletion) of ACE gene and polymorphic variant
20210A ofF2 gene are the genetic markers of the ische-
mic stroke increased risk [23, 24].
Though a lot of promising data concerning the in-
volvement of different allelic variants of genes in deve-
lopment of complex diseases have been published re-
cently, the role of genetic factors in pathogenesis of the-
se disorders is not fully understood. Large-scale whole
genome studies (e. g. HapMap project) using the advan-
ced technologies of genome analysis are considered to
improve the situation.
Determination of genetic factors causing the func-
tional variability of homeostasis maintenance system at
the genomic level opens up the prospects for prediction
of individual features of the disease progression, treat-
ment effectiveness and development of side effects.
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These studies, known as pharmacogenomics, are the
most rapidly growing in the modern world [25–27].
Therefore, informative pharmacogenetic markers tes-
ting before the start of treatment and its monitoring opens
up real prospects for personalized medicine.
In our department the studies on pharmacogenetic
markers effectiveness and development of various side
effects in the treatment of severe and socially important
disease – hepatitis C are being conducted. Recently,
much attention has been paid to the study of IL28B ge-
ne polymorphism, which is a predictor of treatment ef-
ficacy upon using the standard procedure (IFN and
ribavirin). Our results and the results of other resear-
chers show that rs12979860 is a highly informative po-
lymorphic variant marker for prognosis of treatment in
75–80 % cases of patients with chronical hepatitis C,
namely, the individuals carrying hepatitis C virus 1 [28].
It was also shown, that mutations in HFE1 gene, which
cause hereditary hemochromatosis, are associated with
the degree of liver fibrosis in patients with hepatitis C
[29].
It was proven that individuals with certain allelic va-
riants of ITPA gene (94C > A and IVS2 + 21 A > C po-
lymorphic variants) have significantly lower risk of ana-
emia or thrombocytopenia during antiviral therapy [30].
Considering the abovementioned data, the conclu-
sion can be made that the development of highly infor-
mative panel of markers for genetic testing of patients
with hepatitis C will allow the selection of effective in-
dividual treatment schemes based on the principles of
pharmacogenomics.
Also interesting from the viewpoint of perspective
of pharmacogenomics are the results of our studies on
the prevalence of CCR5 gene 32 nucleotide deletion in
Ukrainian population. The heterozygous carriers of the-
se mutations are less sensitive to HIVI virus and the ho-
mozygous carriers are completely resistant to HIVI. In
case of infection of CCR5 gene mutation carriers with
the virus, the latent period lasts much longer and the di-
sease runs in a mild form. The frequency of this muta-
tion in the population of Ukraine is 9.9 % [31, 32]. Thus,
the analysis of CCR5 gene mutation in HIV-infected
individuals may also become an important tool in the
treatment of AIDS.
Copy number variation (CNV’s) studies as a stra-
tegy of search for neurodegenerative disease candi-
date genes. The studies of the human genome variabi-
lity revealed a new type of mutations/polymorphisms
in the genome – CNV [33]. Most of these genomic va-
riations are neutral polymorphisms, but there are dosage
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Fig. 5. Polymorphic
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sensitive genes, in which genomic CNV caused by dele-
tions and duplications of individual genomic loci leads
to the development of various pathologies. Due to the
development of advanced methods of whole genome
screening during the last years a large number of patho-
logical conditions associated with chromosomal reorga-
nizations, that lead to changes of genes copy number,
have been identified [33, 34].
There is a hypothesis according to which the vast
majority of pathogenic CNVs contain genes involved
in the formation and functioning of the nervous system
[35]. This suggestion could be explained by the extraor-
dinary sensitivity of nervous tissues to various endoge-
nous and exogenous factors. The use of advanced me-
thods of genome analysis allows the mapping of geno-
mic loci and identifying the dosage sensitive candidate
genes of various neurodegenerative and neuropsychiat-
ric diseases.
Using qPCR method, the efficient copy number ana-
lysis assays were developed for the determination of
gene copy number for genomic loci in which patho-
genic CNV’s are associated with the development of
neurodegenerative diseases: analysis of hereditary poly-
neuropathies associated with copy number changes of
ÐÌÐ22 gene in 17ð11.2 chromosomal region; copy
number analysis of highly homologous genes SMN1
(SMA determining gene) and SMN2 (supposed SMA
phenotype modifying gene) [12, 36]. The investigation
of the prevalence and origin of CNVs in 17p11.2
(including PMP22 gene) and 5q13.1 (including SMN1
and SMN2 genes) loci in patients with CMT1 and SMA
using qPCR-based copy number analysis was carried
out and allowed us to define their role in the
development of pathologies.
In the frame of international FP7 CHERISH project
the identifying of candidate genes that cause intellectual
disability (ID) was carried out. Using MLPA (multiplex
ligation-dependent probe amplification) method, the
analysis of genomic microdeletions/ microduplications
and subtelomeric deletions/duplications associated with
ID was performed. During the project a strategy for eve-
ry unique CNV confirmation, identified by array CGH
screening, and their origin determination using qPCR
was developed. The results of the CHERISH project in
Ukraine revealed at least 18 unique novel probably pa-
thogenic CNV’s (deletions and/or duplications), that in-
clude potential candidate genes associated with patho-
genic phenotypes in patients [37]. It should be noted,
that the identification of small-sized CNVs, containing
several possible candidate genes, is a rare event, but the-
se findings make it easy to identify the candidate genes.
Most of the identified rearrangements contain from tens
to hundreds of genes, which greatly complicates the
search. Further study of these reorganizations, especial-
ly comparative analysis of genotype-phenotype associa-
tions in patients with different-sized CNVs in the same
chromosomal loci will detect the common areas and iden-
tify new genes involved in the pathogenesis of ID. By
this time the processing of the results continues.
Conclusions. Summarizing the results of own re-
search in the past 25 years and assessing the current
state of human genomics it is worth to note the progress
in studies of mutation associated with monogenic disor-
ders origin, their correlation with phenotype and role of
modifying genes in heterogeneity of clinical features for
monogenic disorders. Important achievements were re-
ached in the understanding of genome polymorphism
involvement in susceptibility to complex disorders. It is
necessary to join the efforts of many scientists in large-
scale whole genome multidisciplinary studies and to de-
velop a system human biology concept in order to achie-
ve complete understanding of the genome. This will al-
low identifying genes causing rare pathologies and sus-
ceptibility to common complex diseases.
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Äîñë³äæåííÿ ìóòàö³é òà ðåîðãàí³çàö³é â ãåíîì³ ëþäèíè – øëÿõ äî
ç’ÿñóâàííÿ ïàòîãåíåçó ìîíîãåííèõ ³ ìóëüòèôàêòîðíèõ çàõâîðþâàíü
Ðåçþìå
Ï³äñóìîââàíî ðåçóëüòàòè 25-ë³òí³õ äîñë³äæåíü ñï³âðîá³òíèê³â
â³ää³ëó ãåíîì³êè ëþäèíè ²ÌÁ³Ã ÍÀÍ Óêðà¿íè, ñïðÿìîâàíèõ íà ç’ÿ-
ñóâàííÿ ìîëåêóëÿðíî-ãåíåòè÷íî¿ ïðèðîäè, ñïåêòðà ³ ïîõîäæåííÿ
â ïîïóëÿö³¿ Óêðà¿íè ìóòàö³é (ãåíåòè÷íèõ ïîë³ìîðô³çì³â) òà ðåîð-
ãàí³çàö³é êîäóþ÷èõ ³ íåêîäóþ÷èõ ä³ëÿíîê ãåíîìó ëþäèíè. Âñòàíîâ-
ëåíî ðîëü ãåòåðîãåííîñò³ ãåíîìó â ïàòîãåíåç³ òÿæêèõ ìîíîãåí-
íèõ ³ ìóëüòèôàêòîðíèõ ïàòîëîã³é. Îòðèìàíî äàí³ ùîäî êîðå-
ëÿö³¿ ïåâíèõ ìóòàö³é ãåí³â-äåòåðì³íàòîð³â ç ôåíîòèïîâèìè ïðî-
ÿâàìè ìîíîãåííèõ çàõâîðþâàíü, à òàêîæ îáãîâîðåíî ðîëü ãåí³â-
ìîäèô³êàòîð³â ó âàð³àö³ÿõ êë³í³÷íîãî ôåíîòèïó. Äîñë³äæåíî ïî-
õîäæåííÿ îêðåìèõ ìóòàíòíèõ àëåë³â òà çíàéäåíî îñíîâí³ çàêî-
íîì³ðíîñò³ ïðîöåñ³â ï³äòðèìàííÿ ¿õíüî¿ ÷àñòîòè â ïîïóëÿö³¿ Óê-
ðà¿íè. Ïðåäñòàâëåíî äàí³ ñòîñîâíî àñîö³àö³¿ äåÿêèõ ïîë³ìîðôíèõ
âàð³àíò³â ç áåçïë³ääÿì, ñåðöåâî-ñóäèííèìè çàõâîðþâàííÿìè (³øå-
ì³÷íèé ³íñóëüò), à òàêîæ ç ìàñîâèìè ³íôåêö³éíèìè õâîðîáàìè
(ãåïàòèò Ñ, ÑÍ²Ä) òà ïîêàçàíî åôåêòèâí³ñòü ñòàíäàðòíî¿ òå-
ðàï³¿. Ïðîäåìîíñòðîâàíî ïåðø³ ðåçóëüòàòè ³ ïåðñïåêòèâè íîâî¿
ñòðàòåã³¿ ïîøóêó ãåí³â – ìàðêåð³â íåéðîäåãåíåðàòèâíèõ çàõâîðþ-
âàíü òà ³íòåëåêòóàëüíî¿ íåä³ºçäàòíîñò³ çà ðàõóíîê ïîâíîãåíîì-
íîãî ñêðèí³íãó ãåíîìíèõ ðåîðãàí³çàö³é òèïó CNV.
Êëþ÷îâ³ ñëîâà: ãåíîì³êà ëþäèíè, ãåíîòèï, ôåíîòèï, ãåíåòè÷-
íèé ïîë³ìîðô³çì, ãåíåòè÷íèé ìàðêåð.
Ë. À. Ëèâøèö, Ñ. À. Êðàâ÷åíêî, Ì. Â. Íå÷èïîðåíêî, Â. Í. Ïàìïóõà,
Í. Â. Ãðèùåíêî, À. Á. Ëèâøèö, À. À. Ñîëîâüåâ, Ï. Ô. Òàòàðñêèé,
Î. À. Ôåñàé, Ñ. Þ. ×åðíóøèí, À. Ì. Êó÷åðåíêî, Ð. Â. Ãóëêîâñêèé
Èññëåäîâàíèå ìóòàöèé è ðåîðãàíèçàöèé â ãåíîìå ÷åëîâåêà – ïóòü ê
âûÿñíåíèþ ïàòîãåíåçà ìîíîãåííûõ è ìóëüòèôàêòîðíûõ çàáîëåâàíèé
Ðåçþìå
Îáîáùåíû ðåçóëüòàòû 25-ëåòíèõ èññëåäîâàíèé ñîòðóäíèêîâ îò-
äåëà ãåíîìèêè ÷åëîâåêàÈÌÁèÃÍÀÍÓêðàèíû, íàïðàâëåííûõ íà âû-
ÿñíåíèå ìîëåêóëÿðíî-ãåíåòè÷åñêîé ïðèðîäû, ñïåêòðà è ïðîèñ-
õîæäåíèÿ â ïîïóëÿöèè Óêðàèíû ìóòàöèé (ãåíåòè÷åñêèõ ïîëèìîð-
ôèçìîâ) è ðåîðãàíèçàöèé â êîäèðóþùèõ è íåêîäèðóþùèõ ó÷àñò-
êàõ ãåíîìà ÷åëîâåêà. Óñòàíîâëåíà ðîëü ãåòåðîãåííîñòè ãåíîìà â
ïàòîãåíåçå òÿæåëûõ ìîíîãåííûõ è ìóëüòèôàêòîðíûõ ïàòîëî-
ãèé. Ïîëó÷åíû äàííûå î êîððåëÿöèè îïðåäåëåííûõ ìóòàöèé ãåíîâ-
äåòåðìèíàòîðîâ ñ ôåíîòèïè÷åñêèìè ïðîÿâëåíèÿìè ìîíîãåííûõ
çàáîëåâàíèé, à òàêæå îáñóæäåíà ðîëü ãåíîâ-ìîäèôèêàòîðîâ â
âàðèàöèÿõ êëèíè÷åñêîãî ôåíîòèïà. Èññëåäîâàíî ïðîèñõîæäåíèå
îòäåëüíûõ ìóòàíòíûõ àëëåëåé è óñòàíîâëåíû îñíîâíûå çàêîíî-
ìåðíîñòè ïðîöåññîâ ïîääåðæàíèÿ èõ ÷àñòîòû â ïîïóëÿöèè Óêðà-
èíû. Ïðåäñòàâëåíû äàííûå îá àññîöèàöèè íåêîòîðûõ ïîëèìîðô-
íûõ âàðèàíòîâ ñ áåñïëîäèåì, ñåðäå÷íî-ñîñóäèñòûìè çàáîëåâàíè-
ÿìè (èøåìè÷åñêèé èíñóëüò), à òàêæå ñ ìàññîâûìè èíôåêöèîííû-
ìè áîëåçíÿìè (ãåïàòèò Ñ, ÑÏÈÄ) è ïîêàçàíà ýôôåêòèâíîñòü
ñòàíäàðòíîé òåðàïèè. Ïðîäåìîíñòðèðîâàíû ïåðâûå ðåçóëüòà-
òû è ïåðñïåêòèâû íîâîé ñòðàòåãèè ïîèñêà ãåíîâ – ìàðêåðîâ íåé-
ðîäåãåíåðàòèâíûõ çàáîëåâàíèé è èíòåëëåêòóàëüíîé íåäååñïîñîá-
íîñòè çà ñ÷åò ïîëíîãåíîìíîãî ñêðèíèíãà ãåíîìíûõ ðåîðãàíèçà-
öèé òèïà CNV.
Êëþ÷åâûå ñëîâà: ãåíîìèêà ÷åëîâåêà, ãåíîòèï, ôåíîòèï, ãåíå-
òè÷åñêèé ïîëèìîðôèçì, ãåíåòè÷åñêèé ìàðêåð.
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